Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
REDEEM-CAD
1 other identifier
observational
748
1 country
2
Brief Summary
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2023
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 4, 2022
CompletedFirst Posted
Study publicly available on registry
May 9, 2022
CompletedStudy Start
First participant enrolled
October 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2026
CompletedDecember 4, 2025
September 1, 2025
2.5 years
May 4, 2022
November 27, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of evaluated patients who should undergo CAD prevention
High clinical risk, or intermediate risk with CAC score \>0
3 years
Secondary Outcomes (3)
Proportion with critical CAD
3 years
Proportion at intermediate clinical risk
3 years
Statin responsiveness
3 year follow-up
Study Arms (2)
Survivor Screening/Management Plan
In cancer survivors; 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
Non-cancer Screening/Management Plan
In matched non-cancer patients (from EDCAD trial); 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
Interventions
Screening/Management Plan
Eligibility Criteria
Cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago
You may qualify if:
- A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
You may not qualify if:
- Unable to provide written informed consent to participate in this study
- Known coronary artery disease at recruitment
- History of previous coronary artery disease
- Inability to acquire interpretable CT images
- Contraindications/Intolerance to or already taking statin therapy
- Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Baker Heart and Diabetes Institutelead
- Western Health, Australiacollaborator
- Northern Hospital, Australiacollaborator
- Menzies Institute for Medical Researchcollaborator
- Peter MacCallum Cancer Centre, Australiacollaborator
- The Alfredcollaborator
Study Sites (2)
Tom Marwick
Hobart, Tasmania, 7000, Australia
Baker Heart and Diabetes Institute
Melbourne, Victoria, 3004, Australia
Related Publications (1)
Soh CH, Smith J, Shrestha S, Nolan M, Wong J, Nerlekar N, Marwick TH. Screening for coronary artery disease among cancer survivors: rationale and design of the REDEEM-CAD study. Cardiooncology. 2025 Feb 4;11(1):10. doi: 10.1186/s40959-025-00308-7.
PMID: 39905553DERIVED
Biospecimen
Coronary CT scans
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tom Marwick, MBBS,PhD,MPH
Baker Heart and Diabetes Institute
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 4, 2022
First Posted
May 9, 2022
Study Start
October 18, 2023
Primary Completion
May 1, 2026
Study Completion
May 1, 2026
Last Updated
December 4, 2025
Record last verified: 2025-09